Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

4.04USD
4:00pm EDT
Change (% chg)

$-0.15 (-3.58%)
Prev Close
$4.19
Open
$4.19
Day's High
$4.28
Day's Low
$4.01
Volume
36,586
Avg. Vol
106,941
52-wk High
$7.28
52-wk Low
$3.29

GNCA.OQ

Chart for GNCA.OQ

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 2.30
Market Cap(Mil.): $120.14
Shares Outstanding(Mil.): 28.67
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 58.88 32.14
EPS (TTM): -2.04 -- --
ROI: -97.45 -0.12 13.99
ROE: -127.17 2.88 15.33

BRIEF-Genocea Biosciences reports qtrly loss per share $‍0.54​

* Genocea Biosciences reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Genocea biosciences Q1 loss per share $0.48

* Genocea reports first quarter 2017 financial results and positive clinical developments on lead candidate gen-003 in genital herpes

May 04 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF80.65 -1.30
Pfizer Inc. (PFE.N) $32.95 -0.41
Merck & Co., Inc. (MRK.N) $61.81 -0.89
Sanofi SA (SASY.PA) €82.76 --
AstraZeneca plc (AZN.L) 4,481.00 +13.50
GlaxoSmithKline plc (GSK.L) 1,506.00 +2.00
Vical Incorporated (VICL.OQ) $2.40 -0.03

Earnings vs. Estimates